Efficacy and safety of dapagliflozin on kidney and cardiovascular outcomes by baseline albuminuria: a secondary analysis of the DAPA-CKD trial

被引：0
|
作者：
Heerspink, H. J. Lambers [1 ]
Waijer, S. W. [1 ]
Vart, P. [1 ]
Cherney, D. Z. I. [2 ]
Chertow, G. [3 ]
Langkilde, A. M. [4 ]
McMurray, J. J. V. [5 ]
Rossing, P. [6 ]
Correa-Rotter, R. [7 ]
Stefansson, B. V. [4 ]
Toto, R. [8 ]
Wheeler, D. [9 ]
机构：
[1] Univ Med Ctr Groningen, Groningen, Netherlands
[2] Univ Toronto, Toronto, ON, Canada
[3] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[4] AstraZeneca, Gothenburg, Sweden
[5] Univ Glasgow, Glasgow, Lanark, Scotland
[6] Steno Diabet Ctr, Copenhagen, Denmark
[7] Natl Med Sci & Nutr Inst Salvador Zubiran, Mexico City, DF, Mexico
[8] UCL, Dept Internal Med, London, England
[9] UCL, Dept Renal Med, London, England
来源：
DIABETOLOGIA | 2021年 / 64卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
51
引用
收藏
页码：30 / 30
页数：1
相关论文
共 50 条
  • [41] Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD A Secondary Analysis of the SCORED Trial
    Sridhar, Vikas S.
    Bhatt, Deepak L.
    Odutayo, Ayodele
    Szarek, Michael
    Davies, Michael J.
    Banks, Phillip
    Pitt, Bertram
    Steg, Ph. Gabriel
    Cherney, David Z. I.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 19 (05): : 557 - 564
  • [42] Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trial
    Zhang, Zhiyan
    Heerspink, Hiddo J. L.
    Chertow, Glenn M.
    Correa-Rotter, Ricardo
    Gasparrini, Antonio
    Jongs, Niels
    Langkilde, Anna Maria
    McMurray, John J., V
    Mistry, Malcolm N.
    Rossing, Peter
    Toto, Robert
    Vart, Priya
    Nitsch, Dorothea
    Wheeler, David C.
    Caplin, Ben
    LANCET PLANETARY HEALTH, 2024, 8 (04): : e225 - e233
  • [43] Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial
    Heerspink, Hiddo J. L.
    Greasley, Peter J.
    Ahlstrom, Christine
    Althage, Magnus
    Dwyer, Jamie P.
    Law, Gordon
    Wijkmark, Emma
    Lin, Min
    Mercier, Anne-Kristina
    Sunnaker, Mikael
    Turton, Michelle
    Wheeler, David C.
    Ambery, Philip
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 (03) : 414 - 425
  • [44] Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial (vol 9, pg 743, 2021)
    Heerspink, H. J. L.
    Jongs, N.
    Chertow, G. M.
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (10): : E10 - E10
  • [45] THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH EGFR <30 ML/MIN/1.73M2: FINDINGS FROM THE DAPA-CKD TRIAL
    Chertow, G.
    Vart, P.
    Jongs, N.
    Toto, R.
    Gorriz, J. L.
    Hou, F. F.
    Mcmurray, J.
    Correa-Rotter, R.
    Rossing, P.
    Sjostrom, C. D.
    Stefansson, B. V.
    Langkilde, A. M.
    Wheeler, D. C.
    Heerspink, H. J. L.
    NEPHROLOGY, 2021, 26 : 33 - 34
  • [46] Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants
    Olufade, Tope
    Lamerato, Lois
    Sanchez, Juan Jose Garcia
    Jiang, Like
    Huang, Joanna
    Nolan, Stephen
    Rangaswami, Janani
    ADVANCES IN THERAPY, 2021, 38 (02) : 1352 - 1363
  • [47] Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants
    Tope Olufade
    Lois Lamerato
    Juan José García Sánchez
    Like Jiang
    Joanna Huang
    Stephen Nolan
    Janani Rangaswami
    Advances in Therapy, 2021, 38 : 1352 - 1363
  • [48] The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics
    McMurray, John J. V.
    DeMets, David L.
    Inzucchi, Silvio E.
    Kober, Lars
    Kosiborod, Mikhail N.
    Langkilde, Anna Maria
    Martinez, Felipe A.
    Bengtsson, Olof
    Ponikowski, Piotr
    Sabatine, Marc S.
    Sjostrand, Mikaela
    Solomon, Scott D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 (11) : 1402 - 1411
  • [49] APPLYING LANDMARK DECLARE, DAPA-CKD, DAPA HE AND DELIVER TRIAL FINDINGS IN US ADULTS WITH CARDIOMETABOLIC AND RENAL DISEASES: MEDICAL CARE COST -OFFSETS ASSOCIATED WITH DAPAGLIFLOZIN COMPARED TO STANDARD OF CARE
    Chang, Raymond
    Miller, Ryan
    Huang, Joanna
    Kwon, Katherine
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (04) : S155 - S155
  • [50] AMBIENT HEAT EXPOSURE AND ESTIMATED GLOMERULAR FILTRATION RATE TRAJECTORY: A POST-HOC ANALYSIS OF THE DAPA-CKD TRIAL
    Zhang, Zhiyan
    Ileerspink, Hiddo Lambers
    Chertow, Glenn
    Correa-Rotter, Ricardo
    Gasparrini, Antonio
    Jong, Niels
    Langkilde, Anna Maria
    Mistry, Malcolm
    Mcmurray, John
    Rossing, Peter
    Toto, Robert
    Vart, Priya
    Misch, Dorothea
    Wheeler, David C.
    Ben Caplin
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I472 - I472
12345